@carcar_7171's Wegovy struggles fact-checked
Quick answer
The creator is at week three of Wegovy, almost certainly still on the 0.25 mg titration dose, which is below the therapeutic threshold for meaningful weight loss. Her reported fatigue is consistent with documented CNS-mediated adverse effects of semaglutide in early treatment, affecting roughly 11% of users in phase 3 trials. A clinical review of injection timing, dose progression, and baseline metabolic markers would be appropriate before concluding the medication is ineffective or contraindicated for her.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @carcar_7171 actually say?
The creator says Wegovy is making her "way too tired" at week three, to the point her "eyes feel heavy" shortly after injecting. She also says it is "not really helping with weight loss" and she's considering switching to something else. These are two separate claims worth pulling apart.
The fatigue complaint is specific and time-stamped. She noticed it after this morning's injection and says it has not subsided across three weeks. The weight loss complaint is vaguer, but week three on the starting dose of 0.25 mg is almost universally too early to see meaningful scale movement. Those two issues deserve very different responses.
Does the science back this up?
On fatigue: yes, more than most providers acknowledge upfront. Clinical trial data consistently shows fatigue as a reported adverse event. In the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), fatigue was reported by roughly 11% of participants on semaglutide versus 4% on placebo. That is a real signal, not a nocebo effect.
The timing she describes, feeling it within hours of injecting, is also plausible. Semaglutide works partly through central nervous system pathways, including GLP-1 receptors in the brainstem that regulate energy balance. Activating those receptors can produce sedation-adjacent effects, particularly early in treatment when the body is not yet adapted. A 2022 review by Blundell et al. in Diabetes, Obesity and Metabolism noted that CNS-mediated effects of GLP-1 agonists include altered arousal and appetite signaling, which can manifest as fatigue in the short term.
On weight loss at week three: the starting dose of Wegovy (0.25 mg weekly) is a titration dose, not a therapeutic dose. Expecting meaningful fat loss this early is not supported by the pharmacology.
What did they get wrong (or right)?
She is mostly right about the fatigue being real, and deserves credit for tracking it precisely. But she conflates two separate problems into one conclusion: "my body's not liking it." That framing is where things get shaky.
Saying the drug "is not working" at week three on 0.25 mg is premature. The STEP trials reached full dosing (2.4 mg) over 16 to 20 weeks, and peak weight loss was observed at 68 weeks. Judging efficacy at week three is like leaving a movie after the opening credits. It is not a fair test.
She also implies that persistent fatigue means she is "somebody that it's not going to work for," which is not how GLP-1 response actually works. Non-responders exist, but they are identified by lack of weight loss at therapeutic doses over months, not by side effects at starter doses. Fatigue and efficacy are not the same axis.
What she got right: GLP-1 side effects do vary significantly between individuals. Some people tolerate semaglutide poorly and do better on tirzepatide or liraglutide. That instinct is not wrong. It just needs a clinician conversation, not a self-directed quit.
What should you actually know?
Fatigue on Wegovy is documented and underreported in patient education materials. If it is severe or lasting, that is a legitimate reason to contact your prescriber, not just push through. In some cases, the timing of the injection (morning versus evening) can shift when the fatigue hits, making it more manageable. Some patients find moving to an evening dose helps them sleep through the worst of it.
Three weeks is also not long enough to assess weight loss response on semaglutide. A 2022 analysis by Rubino et al. in JAMA found that clinically meaningful weight loss, defined as at least 5% body weight, typically begins emerging between weeks 12 and 20 at therapeutic doses. Week three at 0.25 mg is genuinely not a data point.
If fatigue does not resolve after dose titration, that is a different conversation. Persistent, debilitating fatigue warrants a clinical evaluation, including thyroid function, since GLP-1-related nausea and appetite suppression can occasionally mask other issues. Do not self-diagnose a treatment failure. Talk to a provider.
- Fatigue affects roughly 11% of semaglutide users per STEP 1 trial data
- CNS mechanisms of GLP-1 agonists can explain injection-proximate tiredness
- Week three at starter dose is too early to evaluate efficacy
- Individual variation in tolerability is real and worth a provider conversation
- Switching medications is a valid option, but should be a clinical decision
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @carcar_7171's Wegovy struggles fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The creator is at week three of Wegovy, almost certainly still on the 0.
FormBlends verdict
The creator is at week three of Wegovy, almost certainly still on the 0.25 mg titration dose, which is below the therapeutic threshold for meaningful weight loss. Her reported fatigue is consistent with documented CNS-mediated adverse effects of semaglutide in early treatment, affecting roughly 11% of users in phase 3 trials. A clinical review of injection timing, dose progression, and baseline metabolic markers would be appropriate before concluding the medication is ineffective or contraindicated for her.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is at week three of Wegovy, almost certainly still on the 0.25 mg titration dose, which is below the therapeutic threshold for meaningful weight loss. Her reported fatigue is consistent with documented CNS-mediated adverse effects of semaglutide in early treatment, affecting roughly 11% of users in phase 3 trials. A clinical review of injection timing, dose progression, and baseline metabolic markers would be appropriate before concluding the medication is ineffective or contraindicated for her.
- STEP 1 trial (Wilding et al., 2021, NEJM): fatigue occurred in 11% of semaglutide users versus 4% on placebo, confirming it is a real drug effect, not imagination.
- The 0.25 mg starting dose of Wegovy is a titration dose only. It is not the therapeutic dose and is not expected to produce weight loss.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- STEP 1 trial (Wilding et al., 2021, NEJM): fatigue occurred in 11% of semaglutide users versus 4% on placebo, confirming it is a real drug effect, not imagination.
- The 0.25 mg starting dose of Wegovy is a titration dose only. It is not the therapeutic dose and is not expected to produce weight loss.
- Rubino et al. (2022, JAMA) found meaningful weight loss on semaglutide typically begins between weeks 12 and 20, making week-three assessments unreliable.
- Injection timing adjustment, morning to evening or vice versa, is a low-risk strategy that some patients use to shift fatigue to sleeping hours. Ask your prescriber.
- GLP-1 receptors in the brainstem influence arousal and energy state, which is why CNS-mediated fatigue can appear quickly after injection, not hours later as GI effects might.
- Individual variation in tolerability between semaglutide and tirzepatide is documented. Switching is a legitimate clinical option, but requires a provider conversation, not a solo decision.
- Persistent, severe fatigue that does not improve with titration warrants a clinical workup, including thyroid panel, before attributing it entirely to the medication.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
carcar_7171 · TikTok creator
12.3K views on this video
It’s not working for me 😭 #wegovy #weightloss
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by carcar_7171, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.